Immune response to histotripsy in colorectal cancer liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, open-label, single-arm pilot enrolls adults with biopsy-proven microsatellite-stable colorectal cancer and at least one radiographically confirmed liver metastasis who are planned for standard-of-care histotripsy. Investigators will collect serial blood samples before and after the procedure to measure peripheral T‑cell clonal expansion and markers of T‑cell exhaustion over time. The study aims to characterize systemic immune changes following local tumor disruption in a setting known for an immune‑tolerant liver microenvironment. Results are intended to inform whether histotripsy could be combined with immunotherapies in future trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Gender: Both male and female patients will be eligible for enrollment.

  * Age at least 18 years.
  * Histologic (biopsy-proven) confirmation of metastatic microsatellite stable colorectal cancer with at least one radiographically evident hepatic metastasis.
  * Planned treatment with standard-of-care histotripsy.
  * Radiographic confirmation of hepatic metastases with computed tomography (CT) or magnetic resonance imaging (MRI), with CT preferred. Imaging must be performed within 60 days of the date of consent.
  * Adequate organ and marrow function as defined below:

    1. Absolute neutrophil count: ≥ 1,000/mcL
    2. Platelets: ≥ 100,000/mcL
    3. Total bilirubin ≤ 3x the upper limit of normal (ULN). This may be up to 5x ULN if Gilbert's syndrome is documented.
    4. AST and ALT ≤ 8x institutional ULN.
    5. Serum creatinine ≤ 2x ULN unless on dialysis.
  * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3.
  * Estimated life expectancy of at least 90 days as determined by the treating physician.
  * Demographic group: There are no restrictions based on race or ethnicity. Efforts will be made to ensure a representative patient population reflecting the diversity of individuals affected by CRCLM.
  * Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

* Major surgical procedure or significant traumatic injury within 14 days prior to histotripsy.

  * Therapy with an investigational drug within 14 days prior to histotripsy.
  * Clinically significant cardiovascular or cerebrovascular disease, including:

    * Myocardial infarction within 3 months prior to enrollment.
    * Unstable angina.
    * Congestive heart failure (New York Heart Association Classification Class \> II).

      v. 3.0 22July2025 9
    * Serious cardiac arrhythmia (controlled atrial fibrillation or definitively treated arrhythmias via ablation are not considered exclusion criteria).
    * Cerebrovascular stroke with deficit within 3 months prior to enrollment.
  * Active infection requiring systemic therapy within 14 days prior to histotripsy, unless deemed to be a chronic disease state by the study PI.
  * Active pregnancy.
  * Patients with active infections, autoimmune diseases requiring systemic immunosuppression, or other uncontrolled comorbidities that could interfere with study participation will be excluded.
  * Severe cancer-associated cachexia that may interfere with systemic immune response, as assessed by the treating physician.
  * Any ongoing medical illness or injury that would significantly impact tolerability of therapy, including but not limited to:

    * Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture.
    * Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding.
    * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates histotripsy, may affect the interpretation of study results, or may render the patient at high risk for treatment complications.
  * Anyone that is unable to consent due to cognitive, psychological or other reasons that impact their capacity.
  * Deemed to be inappropriate for enrollment by the study PI.

Where it's running

• Zuckerberg Cancer Center
  New Hyde Park, New York, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Perioperative biomarker monitoring to spot complications after colorectal and gastric cancer surgery

  This randomized trial tests whether checking inflammatory and metabolic biomarkers during the perioperative period helps detect postoperative problems early in adults having colorectal or gastric cancer surgery.

  Recruiting Bucharest Emergency Hospital · Bucharest, Bucharest · NCT07881133

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• BHB810 in advanced gastric and GEJ cancer (early-phase)

  This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.

  Recruiting at 2 sites Phase 1/2 BigHat Biosciences, Inc. · Duarte, California and 2 other locations · NCT07529808

• Biopsy and Resection Growth Patterns in Colorectal Peritoneal Cancer

  This study tests whether peritoneal growth patterns seen on small biopsies during staging laparoscopy match the patterns found in later surgical specimens for adults with colorectal peritoneal metastases.

  Recruiting Jules Bordet Institute · Brussels, Brussels Capital and 1 other locations · NCT07474025

• RC148 plus chemotherapy as first-line treatment for unresectable or metastatic colorectal cancer

  This study tests RC148 with standard chemotherapy as the first treatment for people with unresectable or metastatic colorectal cancer to see if it helps more than current therapy.

  Recruiting at 19 sites Phase 2/3 RemeGen Co., Ltd. · Beijing, Beijing Municipality and 18 other locations · NCT07462143

• Moving the uterus, ovaries, and fallopian tubes out of the pelvis before whole pelvic radiation to preserve fertility.

  This trial tries moving the uterus, ovaries, and fallopian tubes out of the pelvis before whole pelvic radiation in women aged 18–40 who want to preserve their ability to have children.

  Recruiting University of South Florida · Tampa, Florida · NCT07419490

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.